Financials PT Prodia Widyahusada Tbk

Equities

End-of-day quote INDONESIA S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
3,280 ^IDR	+0.61%		-5.48%	-39.26%

Mar. 08	PT Prodia Widyahusada Tbk Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	PT Prodia Widyahusada Tbk Reports Earnings Results for the Nine Months Ended September 30, 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	3,393,750	3,046,875	8,625,000	5,250,000	5,062,500	3,075,000	-	-
Enterprise Value (EV) ²	3,394	1,956	7,150	4,083	5,062	2,135	2,123	3,075
P/E ratio	16.1 x	11.3 x	13.9 x	14.2 x	19.5 x	8.37 x	8.26 x	-
Yield	3.1%	3.45%	1.87%	7.1%	-	6.33%	7.89%	-
Capitalization / Revenue	1.95 x	1.63 x	3.25 x	2.41 x	2.28 x	1.31 x	1.17 x	-
EV / Revenue	1.95 x	1.04 x	2.7 x	1.87 x	2.28 x	0.91 x	0.81 x	-
EV / EBITDA	12 x	5.3 x	8.69 x	7.96 x	10.7 x	3.84 x	3.19 x	-
EV / FCF	-	6.5 x	10.6 x	12.5 x	-	9.28 x	7.25 x	9.35 x
FCF Yield	-	15.4%	9.41%	7.98%	-	10.8%	13.8%	10.7%
Price to Book	2.04 x	1.7 x	3.83 x	2.27 x	-	1.23 x	1.14 x	-
Nbr of stocks (in thousands)	937,500	937,500	937,500	937,500	937,500	937,500	-	-
Reference price ³	3,620	3,250	9,200	5,600	5,400	3,280	3,280	3,280
Announcement Date	3/10/20	3/12/21	3/15/22	3/15/23	3/8/24	-	-	-

¹IDR in Million²IDR in Billions³IDR

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	1,744	1,873	2,652	2,182	2,222	2,347	2,632	-
EBITDA ¹	283.2	369.3	822.6	513.1	474.6	556.4	665.9	-
EBIT ¹	216	301.8	756.6	447	299.1	423.6	483.8	-
Operating Margin	12.39%	16.11%	28.53%	20.49%	13.46%	18.05%	18.38%	-
Earnings before Tax (EBT) ¹	264.8	339.1	786.6	470.3	338.9	468	474	-
Net income ¹	210.3	268.7	621.6	371.6	259.9	367	372	-
Net margin	12.05%	14.35%	23.44%	17.04%	11.69%	15.64%	14.13%	-
EPS ²	224.3	286.7	663.1	394.9	277.2	391.8	397.0	-
Free Cash Flow ³	-	301,134	673,159	325,985	-	230,000	293,000	329,000
FCF margin	-	16,074.41%	25,380.61%	14,942.19%	-	9,800.98%	11,133.01%	-
FCF Conversion (EBITDA)	-	81,533.23%	81,830.9%	63,538.52%	-	41,336.72%	44,003.27%	-
FCF Conversion (Net income)	-	112,051.11%	108,290.56%	87,713.61%	-	62,670.3%	78,763.44%	-
Dividend per Share ²	112.1	112.1	172.0	397.8	-	207.7	258.7	-
Announcement Date	3/10/20	3/12/21	3/15/22	3/15/23	3/8/24	-	-	-

¹IDR in Billions²IDR³IDR in Million

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	-	1,091	1,475	1,167	-	940	952	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ²	-	301,134	673,159	325,985	-	230,000	293,000	329,000
ROE (net income / shareholders' equity)	13.1%	13.5%	30.8%	16.1%	-	14.6%	15.4%	-
ROA (Net income/ Total Assets)	-	12%	25.1%	13.8%	-	12.8%	12.2%	-
Assets ¹	-	2,240	2,475	2,686	-	2,867	3,049	-
Book Value Per Share ³	1,770	1,908	2,402	2,462	-	2,665	2,886	-
Cash Flow per Share ³	-	464.0	829.0	459.0	-	518.0	553.0	-
Capex ¹	-	133	104	134	-	266	255	-
Capex / Sales	-	7.13%	3.93%	6.13%	-	11.34%	9.69%	-
Announcement Date	3/10/20	3/12/21	3/15/22	3/15/23	3/8/24	-	-	-

¹IDR in Billions²IDR in Million³IDR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3,280 IDR

Average target price

6,233 IDR

Spread / Average Target

+90.04%

	1st Jan change	Capi.
PT PRODIA WIDYAHUSADA TBK	-39.26%	189M
SONIC HEALTHCARE LIMITED	-17.86%	8.35B
RADNET, INC.	+39.49%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-38.71%	2.46B
SYNLAB AG	-8.06%	2.47B
DR. LAL PATHLABS LIMITED	-7.96%	2.36B
NEOGENOMICS, INC.	-13.97%	1.78B
FLEURY S.A.	-19.73%	1.53B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.78%	1.21B
METROPOLIS HEALTHCARE LIMITED	+8.32%	1.12B